Clinical and therapeutic aspects of childhood narcolepsy-cataplexy: A retrospective study of 51 children

Sleep

Volumn 33, Issue 11, 2010, Pages 1457-1464

  Aran, Adi ^a   Einen, Mali ^b   Lin, Ling ^b   Plazzi, Guiseppe ^c   Nishino, Seiji ^b   Mignot, Emmanuel ^b  

^a SHAARE ZEDEK MEDICAL CENTER   (Israel)

^b STANFORD UNIVERSITY   (United States)

^c UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Cataplexy; Childhood; DQB1*0602; HLA; Hypocretin; Modafinil; MSLT; Narcolepsy; Orexin; Sodium oxybate; Venlafaxine

Indexed keywords

ATOMOXETINE; CLOMIPRAMINE; FLUOXETINE; HLA DQB1 ANTIGEN; METHYLPHENIDATE; MODAFINIL; OREXIN A; OXYBATE SODIUM; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ADOLESCENT; ARTICLE; CATAPLEXY; CEREBROSPINAL FLUID; CHILD; CHILDHOOD; CLINICAL FEATURE; CONSTIPATION; CONTROLLED STUDY; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPNAGOGIC HALLUCINATION; INSOMNIA; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MONOTHERAPY; NARCOLEPSY; NAUSEA; PARASOMNIA; PHARYNGITIS; POLYSOMNOGRAPHY; PRIORITY JOURNAL; PUBERTY; QUESTIONNAIRE; RETROSPECTIVE STUDY; SCHOOL CHILD; SIDE EFFECT; SOMNOLENCE; TREATMENT WITHDRAWAL; WEIGHT GAIN; WEIGHT REDUCTION; XEROSTOMIA;

EID: 78649896476     PISSN: 01618105     EISSN: 15509109     Source Type: Journal    
DOI: 10.1093/sleep/33.11.1457     Document Type: Article

References (40)

1. Peyron C, Faraco J, Rogers W, et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med 2000;6:991-7.
2. Thannickal TC, Moore RY, Nienhuis R, et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron 2000;27:469-74.
3. Crocker A, Espana RA, Papadopoulou M, et al. Concomitant loss of dynorphin, NARP, and orexin in narcolepsy. Neurology 2005;65:1184-8.
4. Chemelli RM, Willie JT, Sinton CM, et al. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 1999;98:437-51.
5. Lin L, Faraco J, Li R, et al. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 1999;98:365-76.
6. Hara J, Beuckmann CT, Nambu T, et al. Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity. Neuron 2001;30:345-54.
7. Juji T, Satake M, Honda Y, Doi Y. HLA antigens in Japanese patients with narcolepsy. All the patients were DR2 positive. Tissue Antigens 1984;24:316-9.
8. Mignot E, Kimura A, Lattermann A, et al. Extensive HLA class II studies in 58 non-DRB1*15 (DR2) narcoleptic patients with cataplexy. Tissue Antigens 1997;49:329-41.
9. Matsuki K, Grumet FC, Lin X, et al. DQ (rather than DR) gene marks susceptibility to narcolepsy. Lancet 1992;339:1052.
10. Mignot E, Lin L, Rogers W, et al. Complex HLA-DR and -DQ interactions confer risk of narcolepsy-cataplexy in three ethnic groups. Am J Hum Genet 2001;68:686-99.
11. Hallmayer J, Faraco J, Lin L, et al. Narcolepsy is strongly associated with the T-cell receptor alpha locus. Nat Genet 2009;41:708-11.
12. Cvetkovic-Lopes V, Bayer L, Dorsaz S, et al. Elevated Tribbles homolog 2-specific antibody levels in narcolepsy patients. J Clin Invest 2010;120:713-9.
13. Aran A, Lin L, Nevsimalova S, et al. Elevated anti-streptococcal antibodies in patients with recent narcolepsy onset. Sleep. 2009;32:979-83.
14. Okun ML, Lin L, Pelin Z, Hong S, Mignot E. Clinical aspects of narcolepsy-cataplexy across ethnic groups. Sleep 2002;25:27-35. (Pubitemid 34072656)
15. Yoss RE, Daly DD. Narcolepsy in children. Pediatrics 1960;25:1025-33.
16. Honda Y, Asaka A, Tanimura M, Furusho T. A genetic study of narcolepsy and excessive daytime sleepiness in 308 families with a narcolepsy or hypersomnia proband. . In: Guilleminault C, Lugaresi E, eds. Sleep/Wake disorders: Natural History, Epidemiology and Long Term Evolution. New York, NY: Raven; 1983:187-99.
17. Morrish E, King MA, Smith IE, Shneerson JM. Factors associated with a delay in the diagnosis of narcolepsy. Sleep Med. Jan 2004;5(1):37-41.
18. Challamel MJ, Mazzola ME, Nevsimalova S, Cannard C, Louis J, Revol M. Narcolepsy in children. Sleep 1994;17(8 Suppl):S17-20.
19. Guilleminault C, Pelayo R. Narcolepsy in prepubertal children. Ann Neurol 1998;43:135-42.
20. Vendrame M, Havaligi N, Matadeen-Ali C, Adams R, Kothare SV. Narcolepsy in children: a single-center clinical experience. Pediatr Neurol 2008;38:314-20.
21. Dahl RE, Holttum J, Trubnick L. A clinical picture of child and adolescent narcolepsy. J Am Acad Child Adolesc Psychiatry 1994;33:834-41.
22. Han F, Chen E, Wei H, et al. Childhood narcolepsy in North China. Sleep. 2001;24:321-4.
23. Serra L, Montagna P, Mignot E, Lugaresi E, Plazzi G. Cataplexy features in childhood narcolepsy. Mov Disord2008;23:858-65.
24. Ivanenko A, Tauman R, Gozal D. Modafinil in the treatment of excessive daytime sleepiness in children. Sleep Med 2003;4:579-82.
25. Murali H, Kotagal S. Off-label treatment of severe childhood narcolepsy-cataplexy with sodium oxybate. Sleep 2006;29:1025-9.
26. Huang YS, Guilleminault C. Narcolepsy: action of two gamma-aminobutyric acid type B agonists, baclofen and sodium oxybate. Pediatr Neurol 2009;41:9-16.
27. Anic-Labat S, Guilleminault C, Kraemer HC, Meehan J, Arrigoni J, Mignot E. Validation of a cataplexy questionnaire in 983 sleep-disorders patients. Sleep 1999;22:77-87.
28. Koepsell TD, Longstreth WT, Ton TG. Medical exposures in youth and the frequency of narcolepsy with cataplexy: a population-based case-control study in genetically predisposed people. J Sleep Res 2009 Aug 31. [Epub ahead of print]
29. Kotagal S, Krahn LE, Slocumb N. A putative link between childhood narcolepsy and obesity. Sleep Med 2004;5:147-50.
30. Plazzi G, Parmeggiani A, Mignot E, et al. Narcolepsy-cataplexy associated with precocious puberty. Neurology 2006;66:1577-9.
31. Kryger MH, Walid R, Manfreda J. Diagnoses received by narcolepsy patients in the year prior to diagnosis by a sleep specialist. Sleep 2002;25:36-41.
32. Peterson PC, Husain AM. Pediatric narcolepsy. Brain Dev 2008;30):609-23.
33. Wise MS, Lynch J. Narcolepsy in children. Semin Pediatr Neurol 2001;8:198-206.
34. Guilleminault C, Pelayo R. Narcolepsy in children: a practical guide to its diagnosis, treatment and follow-up. Paediatr Drugs 2000;2:1-9.
35. Takahara J, Yunoki S, Yakushiji W, Yamauchi J, Yamane Y. Stimulatory effects of gamma-hydroxybutyric acid on growth hormone and prolactin release in humans. J Clin Endocrinol Metab 1977;44:1014-7.
36. Emslie GJ, Heiligenstein JH, Hoog SL, et al. Fluoxetine treatment for prevention of relapse of depression in children and adolescents: a double-blind, placebo-controlled study. J Am Acad Child Adolesc Psychiatry 2004;43:1397-405.
37. Charach A, Figueroa M, Chen S, Ickowicz A, Schachar R. Stimulant treatment over 5 years: effects on growth. J Am Acad Child Adolesc Psychiatry 2006;45:415-21.
38. Feldman NT. Clinical perspective: monitoring sodium oxybate-treated narcolepsy patients for the development of sleep-disordered breathing. Sleep Breath 2010;14:77-9.
39. George CF, Feldman N, Inhaber N, et al. A safety trial of sodium oxybate in patients with obstructive sleep apnea: acute effects on sleep-disordered breathing. Sleep Med 2010;11:38-42.
40. Wise MS. Childhood narcolepsy. Neurology 1998;50(2 Suppl 1):S37-42.